IDXX · IDEXX Laboratories, Inc.

IDEXX Laboratories reported strong Q1 2026 results with revenue of $1.1 billion, up 14.3% from $998.4 million in the prior year, primarily driven by increases in recurring revenue from higher subscription services volume and higher realized prices. This momentum in recurring streams, particularly within CAG Diagnostics, stemmed from volume gains supported by testing increases across major regions, reflecting benefits from growth in the installed base of premium instruments, expanded test menus, and continued high customer retention rates. The business also saw LPD revenue growth from higher volumes and realized prices.

Gross profit expanded 15.9% to $722.7 million, achieving a 63.4% margin versus the prior period. This improvement reflected benefits from recurring revenue growth in IDEXX VetLab consumables and reference laboratory volumes, operational productivity improvements, and net price realization. These favorable factors more than offset inflationary costs and investments in the business, demonstrating effective cost management and leverage from high-margin recurring diagnostics. Operating income rose 14.5% to $362.6 million with a 31.8% margin, underscoring the scalability of operations even as the company continued to invest in growth initiatives including personnel.

Net income increased 14.7% to $278.4 million, translating to diluted EPS of $3.47, a 17.2% improvement from $2.96. This performance highlights the company's ability to convert top-line growth into bottom-line earnings through disciplined margin management. Cash generation remained robust, with net cash provided by operating activities up to $266.2 million from $238.0 million, after accounting for typical working capital seasonality. Capital expenditures of $31.9 million supported ongoing infrastructure needs, yielding free cash flow of $234.3 million. This strong liquidity position enables continued investment in innovation and customer expansion.

The Other operating segment, encompassing human medical diagnostics and out-licensing, continues without meeting reportable thresholds. Management's commentary emphasizes the durability of recurring revenue models, with gross margin gains driven by lower product costs alongside pricing. At current FX assumptions, anticipated FX tailwinds for the year remainder point to further revenue, operating profit, and EPS uplift. These results position IDEXX well to capitalize on veterinary diagnostics demand amid pet ownership trends and premium instrument adoption.